Taprenepag isopropyl is primarily used in the treatment of glaucoma and ocular hypertension. It functions as a prostaglandin E2 receptor agonist, helping to reduce intraocular pressure by increasing the outflow of aqueous humor from the eye. This makes it effective in managing conditions that could otherwise lead to optic nerve damage and vision loss. It is often prescribed when other treatments are insufficient or unsuitable for the patient. The compound is typically administered as an ophthalmic solution, ensuring direct and targeted action in the eye. Its use is closely monitored by healthcare professionals to ensure optimal therapeutic outcomes and minimize potential side effects.